leisure time -WSS

leisure time

author：knowledge 2025-08-31 13:10:13 - browse：863

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： A rare thyroid diagnosis led to unexpected, all

hotspot

WSS

House transparency, PBM reform bill gains bipartisan support

Senate committee scrutinizes Medicare Advantage brokers

Medicare reduced heart disease by changing how it pays doctors

Advances in CAR

The 10 drugs up first for Medicare price negotiation

A rare thyroid diagnosis led to unexpected, all

knowledge

leisure time

explore

BioMarin wins approval for gene therapy to treat hemophilia A

How to protect patients from sexual assault

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA struggles to regulate food additives, sometimes for decades

State Dept. review finds Biden bears some blame for Afghanistan failures

House transparency, PBM reform bill gains bipartisan support

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Humana sues Biden admin over Medicare Advantage audit rule

How one medical school became remarkably diverse

Eli Lilly expects to double planned employment in Boston center

entertainment

A new House health package & hospitals’ new site

How climate

Pharmacists can make shortage drugs, but at what cost?

Why Novartis is changing the name of its research labs

House transparency, PBM reform bill gains bipartisan support

Amazon on where the company's health care bets are headed next

hotspot

hotspot

knowledge

entertainment